Mylan Found to Have Infringed Medicines Co.’s Patent

The Medicines Co. won a U.S. court ruling that drugmaker Mylan Inc. infringed a patent for its blood-clot-inhibiting drug Angiomax, which accounted for almost 90 percent of Medicines Co.’s revenue last year.

U.S. District Judge Amy J. St. Eve in Chicago, who presided over a non-jury trial in June, today rejected Mylan’s contention that several of the Medicines Co. patent claims were invalid and unenforceable.

An injectable drug, Angiomax is given to patients undergoing angioplasty, a procedure used to clear clogged coronary arteries. It accounted for more than $608.6 million of The Medicines Co.’s almost $688 million in revenue last year.

Mylan had planned to bring a generic form of the drug to market, according to the court’s ruling. The challenged patent expires in January 2029.

Kris King, vice president for investor relations at Canonsburg, Pennsylvania-based Mylan, didn’t immediately reply to voice-mail and e-mail messages seeking comment on the court’s decision. Mylan is scheduled to hold a conference call and live webcast on Oct. 30 to discuss its 2014 third-quarter results, according to its website.

The Medicines Co. is based in Parsippany, New Jersey.

The case is The Medicines Co. v. Mylan Inc., 11-cv-1285, U.S. District Court, Northern District of Illinois (Chicago).

Before it's here, it's on the Bloomberg Terminal.